Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE

por Crauwels, HM, van Schaick, E, van Heeswijk, RPG, Vanveggel, S, Boven, K, Vis, P
Publicado 2010

Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials

por Nelson, M, Amaya, G, Clumeck, N, Arns Da Cunha, C, Jayaweera, D, Junod, P, Taisheng, L, Tebas, P, Stevens, M, Buelens, A, Vanveggel, S, Boven, K
Publicado 2010

Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients

por Cohen, C, Molina, JM, Cahn, P, Clotet, B, Fourie, J, Grinsztejn, B, Hao, W, Johnson, M, Supparatpinyo, K, Crauwels, HM, Rimsky, L, Vanveggel, S, Williams, P, Boven, K
Publicado 2010

Do practice characteristics explain differences in morbidity estimates between electronic health record based general practice registration networks?

por van den Dungen, C, Hoeymans, N, van den Akker, M, Biermans, MCJ, van Boven, K, Joosten, JHK, Verheij, RA, de Waal, MWM, Schellevis, FG, van Oers, JAM
Publicado 2014

The influence of population characteristics on variation in general practice based morbidity estimations

por van den Dungen, C, Hoeymans, N, Boshuizen, HC, van den Akker, M, Biermans, MCJ, van Boven, K, Brouwer, HJ, Verheij, RA, de Waal, MWM, Schellevis, FG, Westert, GP
Publicado 2011